AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|July 14, 2010
Jeff Schindler
Advertisement
Jeff Schindler
Managing Editor
Jeff Schindler received his B.A. in English from the University at Buffalo and immediately began his career at a Long Island music bi-weekly magazine. He quickly moved on to become Associate Editor at Managing Automation magazine, where he covered manufacturing and technology. Jeff came to Pharmaceutical Executive after spending four years at Retailing Today, where he moved up the ranks from Desk Editor to Managing Editor. He has also consulted on special projects for License! Global magazine; startup lifestyle magazine Chagigah; advertising and web copywriting at Quinlan & Co.; as well as copy editing for Demand Studios. Jeff also recently earned a Certificate in Web design from Noble Desktop in New York.
He currently resides in Forest Hills, New York, with his wife, Robyn, and their Siamese cat, Hudson. Jeff is an avid outdoorsman who likes to spend his spare time in the country hiking, biking and skiing, and also plays saxophone and is a novice guitarist. He joined the magazine in July 2010.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
5